ProCE Banner Activity

GADOLIN: Obinutuzumab + Bendamustine and Maintenance Obinutuzumab in Rituximab-Refractory Indolent NHL

Slideset Download
Conference Coverage
The obinutuzumab-containing regimen was associated with a significant reduction in the risk of progression or death compared with bendamustine alone in patients with rituximab-refractory indolent NHL.

Released: June 05, 2015

Expiration: June 03, 2016

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

AstraZeneca

Bayer Healthcare Pharma

Bristol Myers Squibb

Celgene

Genentech BioOncology

Incyte

Novartis Pharmaceuticals Corporation